Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2271-2281
Published online before print April 16, 2007, doi: 10.1161/CIRCULATIONAHA.106.628859
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/17/2271    most recent
CIRCULATIONAHA.106.628859v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, F.
Right arrow Articles by O’Connor, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, F.
Right arrow Articles by O’Connor, D. T.
Related Collections
Right arrow Clinical genetics
Right arrow Hypertension - basic studies
Right arrow Clinical Studies

(Circulation. 2007;115:2271-2281.)
© 2007 American Heart Association, Inc.


Genetics

Catecholamine Release–Inhibitory Peptide Catestatin (Chromogranin A352–372)

Naturally Occurring Amino Acid Variant Gly364Ser Causes Profound Changes in Human Autonomic Activity and Alters Risk for Hypertension

Fangwen Rao, MD; Gen Wen, MD, PhD; Jiaur R. Gayen, PhD; Madhusudan Das, PhD; Sucheta M. Vaingankar, PhD; Brinda K. Rana, PhD; Manjula Mahata, PhD; Brian P. Kennedy, PhD{dagger}; Rany M. Salem, MPH; Mats Stridsberg, PhD; Kenneth Abel, PhD; Douglas W. Smith, PhD; Eleazar Eskin, PhD; Nicholas J. Schork, PhD; Bruce A. Hamilton, PhD; Michael G. Ziegler, MD; Sushil K. Mahata, PhD; Daniel T. O’Connor, MD

From the Departments of Medicine (F.R., G.W., J.R.G., M.D., S.M.V., M.M., B.P.K., R.M.S., K.A., B.A.H., M.G.Z., S.K.M., D.T.O.), Psychiatry (B.K.R., N.J.S.), Computer Science (E.E.), Pharmacology (D.T.O.), and Biology (D.W.S.), Polymorphism Research Laboratory (B.K.R., N.J.S.), and Center for Human Genetics and Genomics (N.J.S., D.T.O.), University of California at San Diego; the VA San Diego Healthcare System (S.K.M., D.T.O.), San Diego, Calif; and the Department of Medical Sciences (M.S.), University of Uppsala, Uppsala, Sweden.

Correspondence to Daniel T. O’Connor, MD, or Sushil K. Mahata, PhD, Department of Medicine and Center for Human Genetics and Genomics (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093–0838. E-mail doconnor{at}ucsd.edu or smahata@ucsd.edu

Received March 31, 2006; accepted November 13, 2006.

Background— Chromogranin A, coreleased with catecholamines by exocytosis, is cleaved to the catecholamine release–inhibitory fragment catestatin. We identified a natural nonsynonymous variant of catestatin, Gly364Ser, that alters human autonomic function and blood pressure.

Methods and Results— Gly364Ser heterozygotes and controls underwent physiological and biochemical phenotyping, including catecholamine production, chromogranin A precursor, and its catestatin product. Case-control studies replicated effects of the gene on blood pressure in the population. Gly364Ser displayed diminished inhibition of catecholamine secretion from cultured neurons. Gly/Ser heterozygotes displayed increased baroreceptor slope during upward deflections (by {approx}47%) and downward deflections (by {approx}44%), increased cardiac parasympathetic index (by {approx}2.4-fold), and decreased cardiac sympathetic index (by {approx}26%). Renal norepinephrine excretion was diminished by {approx}26% and epinephrine excretion by {approx}34% in Gly/Ser heterozygotes. The coalescent dated emergence of the variant to {approx}70 000 years ago. Gly364Ser was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter haplotypes did not predict autonomic phenotypes. The 364Ser variant was associated with lower diastolic blood pressure in 2 independent/confirmatory groups of patients with hypertension; genotype groups differed by {approx}5 to 6 mm Hg, and the polymorphism accounted for {approx}1.8% of population diastolic blood pressure variance, although a significant gene-by-sex interaction existed, with an enhanced effect in men.

Conclusions— The catestatin Gly364Ser variant causes profound changes in human autonomic activity, both parasympathetic and sympathetic, and seems to reduce risk of developing hypertension, especially in men. A model for catestatin action in the baroreceptor center of the nucleus of the tractus solitarius accounts for these actions.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. K. Rana, J. Wessel, V. Mahboubi, F. Rao, J. Haeller, J. R. Gayen, E. Eskin, A. M. Valle, M. Das, S. K. Mahata, et al.
Natural Variation within the Neuronal Nicotinic Acetylcholine Receptor Cluster on Human Chromosome 15q24: Influence on Heritable Autonomic Traits in Twin Pairs
J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 419 - 428.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. R. Gayen, Y. Gu, D. T. O'Connor, and S. K. Mahata
Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse
Endocrinology, November 1, 2009; 150(11): 5027 - 5035.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. Wang, F. Rao, K. Zhang, M. Mahata, J. L. Rodriguez-Flores, M. M. Fung, J. Waalen, M. G. Cockburn, B. A. Hamilton, S. K. Mahata, et al.
Neuropeptide Y(1) Receptor NPY1R discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo.
J. Am. Coll. Cardiol., September 1, 2009; 54(10): 944 - 954.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. B. Helle
The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions
Cardiovasc Res, August 18, 2009; (2009) cvp266v2.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Biswas, J. L. Rodriguez-Flores, M. Courel, J. R. Gayen, S. M. Vaingankar, M. Mahata, J. W. Torpey, L. Taupenot, D. T. O'Connor, and S. K. Mahata
Cathepsin L Colocalizes with Chromogranin A in Chromaffin Vesicles to Generate Active Peptides
Endocrinology, August 1, 2009; 150(8): 3547 - 3557.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. Di Comite, C. M. Rossi, A. Marinosci, K. Lolmede, E. Baldissera, P. Aiello, R. B. Mueller, M. Herrmann, R. E. Voll, P. Rovere-Querini, et al.
Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-{alpha}-elicited endothelial activation
J. Leukoc. Biol., January 1, 2009; 85(1): 81 - 87.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. R. Mahapatra
Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure
Cardiovasc Res, December 1, 2008; 80(3): 330 - 338.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. V. Kabadi and A. Ally
Negative Cardiotropism by Catestatin and Its Variants
Endocrinology, October 1, 2008; 149(10): 4778 - 4779.
[Full Text] [PDF]


Home page
EndocrinologyHome page
T. Angelone, A. M. Quintieri, B. K. Brar, P. T. Limchaiyawat, B. Tota, S. K. Mahata, and M. C. Cerra
The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine/Paracrine Modulator of Cardiac Inotropism and Lusitropism
Endocrinology, October 1, 2008; 149(10): 4780 - 4793.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P.-a. B. Shih and D. T. O'Connor
Hereditary Determinants of Human Hypertension: Strategies in the Setting of Genetic Complexity
Hypertension, June 1, 2008; 51(6): 1456 - 1464.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. M. Salem, P. E. Cadman, Y. Chen, F. Rao, G. Wen, B. A. Hamilton, B. K. Rana, D. W. Smith, M. Stridsberg, H. J. Ward, et al.
Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 600 - 614.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Biswas, S. M. Vaingankar, M. Mahata, M. Das, J. R. Gayen, L. Taupenot, J. W. Torpey, D. T. O'Connor, and S. K. Mahata
Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential Processing at Catestatin Region by Plasmin
Endocrinology, February 1, 2008; 149(2): 749 - 757.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. S. Goldstein
Genotype and Vascular Phenotype Linked by Catecholamine Systems
Circulation, January 29, 2008; 117(4): 458 - 461.
[Full Text] [PDF]